Issue link: https://www.e-digitaleditions.com/i/1509086
42 Pharmaceutical Technology ® Trends in Formulation 2023 eBook PharmTech.com CPHI BarCelona Coverage deep and lasting impact on both efficiency and effec- tiveness of clinical trial recruitment, reducing a signif- icant portion of the overall drug development timeline. Countries commit to AI strategy Globally, there is broad interest in the development and advancement of AI. Several countries are driving the growth and application of AI technologies (9). The United States is the clear leader in AI develop- ment, with tech giants such as Google, Facebook, and Microsoft at the forefront of AI-driven research. China has made substantial investments in AI and is poised to challenge the US as the AI superpower. The Chinese government has prioritized AI develop- ment through its "New Generation Artificial Intelli- gence Development Plan." China's AI ecosystem in- cludes major tech companies such as Baidu, Alibaba, and Tencent. The Chinese government has allocated billions of dollars toward developing the next gener- ation of AI technology, from autonomous vehicles to facial recognition systems. Other countries (10) such as Canada, Japan, and South Korea have made progress with their own ini- tiatives in AI technology. Canada has invested US$125 million to promote research and develop strong talent advances. Japan has made the adoption and incorpo- ration of technology across all sectors of society the center of its future with its "Society 5.0" plan, which aims to ensure that the next generation of students are equipped to harness the capabilities of big data, Internet of Things (IoT), AI, and robots and can fuse these across all social segments. The plan requires that Japan hone its strengths and establish leadership in AI applications in the field of sustainability. South Korea has made a huge commitment to AI by allocating 14 trillion won to the development of AI capabilities. These investments reveal that although China and the US may be dominating headlines when it comes to the AI arms race, there are plenty more competitors looking to take control of this prominent field. Europe may be lagging behind these other countries in terms of AI investment and development, but things are heating up there as well. The European Union (EU) has taken steps to build AI capabilities across the en- tire continent, launching the "AI for Europe" initiative in 2019 to provide an AI development platform for col- laboration and cooperation across member states. France and Germany are not standing idly by ei- ther. In 2022, they announced a program to jointly invest €17.9 million to support five projects to develop new solutions in the field of AI focusing on the areas of sustainability and to make the industry more resil- ient to supply chain disruptions. France has pledged to invest €500 million to create new AI champions. T he U K gover n ment w a s ra n k ed t h i rd i n t he 2021 global AI Readiness Index, and first in Europe. Si nce 2014, t he gover n ment ha s a l located more t han £2.3 bi l lion to t he development of AI. Their Prime Minister, Rishi Sunak, publicly stated10 that he wants to make the United Kingdom not just the intel lect ua l home, but t he geograph ica l home of global AI safety regulation (11). The UK government ha s i nvested more t ha n £100 m i l l ion i n a Fou n- dation Model Task force created to lead AI safet y domestically (11). Since then, the UK has pledged to invest £1 bi l lion to supercomputing and A I re- search as part of its quest to become a "science and technology superpower" (11). Conclusion AI has made notable contributions to healthcare, in- cluding medical image analysis, disease diagnosis, drug discover y, and personalized medicine. Deep learning algorithms show impressive results in accu- rately detecting diseases from medical images, assist- ing radiologists in their diagnoses. AI-powered sys- tems have also accelerated the discovery of potential drug candidates and facilitated the identification of personalized treatment options based on patient-spe- cific data. Progress in AI research and development continues to unlock exciting possibilities and the potential to shape numerous industries in the years to come. AI is transforming the way scientists and re- searchers approach the discovery, development, and production of pharmaceuticals, offering new oppor- tunities to accelerate the entire process, accurately and sustainably. In drug development, AI algorithms are being deployed to analyze vast amounts of data, including genetic information, patient records, and scientific literature. By leveraging machine learning and data mining techniques, AI can identify patterns, predict outcomes, and generate valuable insights that can guide researchers in designing more effective, tar- geted drugs. Not only speeding up the drug discovery process, AI stands to increase the success rate of clin- ical trials by identifying suitable patient populations and reducing potential risks. Although still nascent in its innovation journey, the development and applica- tion curve has been steep, with AI solutions evolving on almost a daily basis. As a significant component of our industry in the next five years, AI will be applied across the value chain, from drug discovery to logis- tics and finance, to become the basis for continued business performance and a catalyst that reduces the cost and time of bringing effective drug therapies to the patients who need them. References 1. CPHI. CPHI Annual Report 2023. www.CPHIOnline. com (accessed Sept 20, 2023). 2. P wC. Sizing the Prize. W hat's the Real Value of A I for Your Business and How Can You Capitalize. PwC